Shallaki

<h3> Absolute Contraindications of Shallaki </h3> <h4>Pregnancy / Trying to conceive [Avoid during pregnancy]</h4> <ul> <li>🤰 <li>Recommendation: Avoid using Shallaki orally or in high-concentration topical forms while pregnant or when trying to conceive; discuss with your healthcare provider before use. <li>Reasoning: Clinical data show Boswellia affects uterine/menstrual bleeding and can shorten menstrual bleeding duration; because it modulates uterine bleeding it is prudent to avoid during pregnancy due to potential effects on uterine tone and bleeding. <li>Scientific_Study_Title: The effect of frankincense (Boswellia serrata, oleoresin) and ginger (Zingiber officinale, rhizoma) on heavy menstrual bleeding: A randomized, placebo-controlled, clinical trial. <li>Scientific_Study_Authors: Razieh Eshaghian, Mohammad Mazaheri, Mustafa Ghanadian, Safoura Rouholamin, Awat Feizi, Mahmoud Babaeian <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/30670277/ <li>Scientific_Study_Excerpt: <p>In a randomized, placebo-controlled study of women with heavy menstrual bleeding, oral frankincense (Boswellia serrata oleoresin 300 mg three times daily alongside ibuprofen) significantly reduced the duration of menstrual bleeding (mean change −1.77 ± 2.47 days; P = 0.003) compared to placebo. The trial authors concluded frankincense had measurable effects on menstrual bleeding and quality of life, indicating Boswellia can influence uterine bleeding patterns. Because pregnancy involves sensitive uterine and circulatory physiology, agents that alter menstrual/uterine bleeding are typically avoided in pregnancy until safety is established.</p> </ul> <h4>On anticoagulation or with bleeding disorders [Layman: taking warfarin or similar blood thinners]</h4> <ul> <li>🩸 <li>Recommendation: Do not take Shallaki without a doctor’s approval if you are on warfarin, direct oral anticoagulants, or have a bleeding disorder; monitoring of clotting tests (e.g., INR) is advised if a clinician permits use. <li>Reasoning: Reports and reviews of herb-drug interactions list Boswellia among herbs implicated in altering anticoagulant effects; laboratory evidence and case summaries suggest herbs can change warfarin activity or bleeding risk. <li>Scientific_Study_Title: Warfarin interactions with medicinal herbs. <li>Scientific_Study_Authors: Natasa Milić, Natasa Milosević, Svetlana Golocorbin Kon, Teodora Bozić, Ludovico Abenavoli, Francesca Borrelli <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/25233607/ <li>Scientific_Study_Excerpt: <p>The review summarizes case reports and literature on herb-warfarin interactions and lists Boswellia serrata among plants implicated in adverse events when combined with warfarin. The authors note severe bleeding events have been reported with concurrent use of warfarin and various herbs, and they emphasize that many herbs (including frankincense/Boswellia) may alter warfarin’s effect through pharmacokinetic or pharmacodynamic mechanisms. Clinicians are urged to be aware and to monitor anticoagulation closely when patients use herbal supplements.</p> </ul> <h4>Known hypersensitivity to Boswellia / topical essential oils [Layman: allergy to frankincense]</h4> <ul> <li>⚠️ <li>Recommendation: If you have a history of allergic skin reactions to frankincense or essential oils, avoid topical or aromatic Shallaki products; if an allergic reaction occurs stop use and seek medical care. <li>Reasoning: Case reports document allergic contact dermatitis after topical Boswellia preparations; people with prior essential oil allergies are at higher risk. <li>Scientific_Study_Title: Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream. <li>Scientific_Study_Authors: Elvira Acebo, Juan Antonio Ratón, Saioa Sautúa, Xabier Eizaguirre, Izaskun Trébol, Jose Luis Díaz Pérez <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15373853/ <li>Scientific_Study_Excerpt: <p>Case reports describe patients developing allergic contact dermatitis after topical use of Boswellia serrata-containing creams. The dermatology report documented localized eczema consistent with contact allergy following exposure to a naturopathic preparation containing Boswellia extract. Patch testing and clinical evaluation implicated the Boswellia component. These clinical observations show that topical Boswellia can cause delayed hypersensitivity reactions in sensitized individuals and support avoiding topical use in those with known sensitivities.</p> </ul> <h3> Relative Contraindications of Shallaki </h3> <h4>Concurrent use with drugs metabolized by hepatic CYP enzymes (e.g., certain statins, antiepileptics, antidepressants)</h4> <ul> <li>⚖️ <li>Recommendation: Discuss with your doctor or pharmacist before combining Shallaki with medications heavily metabolized by CYP isoenzymes (CYP3A4, CYP2C9, CYP2C19); monitoring or dose adjustment may be needed. <li>Reasoning: In vitro analyses show extracts of Boswellia species can inhibit multiple major drug-metabolizing CYP enzymes; while in vitro data do not always translate to clinical interactions, caution is warranted with narrow therapeutic index drugs metabolized by these enzymes. <li>Scientific_Study_Title: Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes. <li>Scientific_Study_Authors: Frank A, Unger M, et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/16364338/ <li>Scientific_Study_Excerpt: <p>Laboratory investigations found that extracts from several Boswellia species (including B. serrata) showed inhibitory activity against multiple human cytochrome P450 enzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4) in vitro. The authors identified boswellic acids among constituents but noted other resin components may contribute to CYP inhibition. The report concluded frankincense extracts have the potential to alter hepatic drug metabolism and therefore could affect plasma concentrations of co-administered drugs processed by these CYP enzymes.</p> </ul> <h4>Severe liver disease / impaired hepatic function</h4> <ul> <li>🧪 <li>Recommendation: Use with caution and only under medical supervision if you have significant liver impairment; clinicians may prefer to avoid until more human safety data are available. <li>Reasoning: Some experimental studies indicate Boswellia extracts can modulate hepatic enzyme expression; while clinical hepatotoxicity reports are rare, altered hepatic metabolism and potential metabolite effects suggest caution in severe hepatic dysfunction. <li>Scientific_Study_Title: Boswellia carteri resin extract induces phase-I cytochrome P-450 enzyme gene expressions in human hepatocarcinoma (Hep G2) cells: in vitro and in silico studies. <li>Scientific_Study_Authors: Alghamdi A, et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/40352903/ <li>Scientific_Study_Excerpt: <p>An in vitro/in silico study of Boswellia carteri resin found aqueous extracts could modulate expression of major phase-I CYP enzymes (CYP1A2, CYP2B6, CYP3A4) in Hep G2 cells, potentially via activation of nuclear receptors such as CAR. The authors highlight that altered CYP expression could change drug metabolism and raise toxicological concerns; they recommend caution and call for in vivo confirmation. Although not direct clinical liver injury evidence, the data support prudence in individuals with impaired hepatic function.</p> </ul> <h4>Breastfeeding (lactation)</h4> <ul> <li>🍼 <li>Recommendation: Avoid high-dose oral Shallaki while breastfeeding unless a clinician advises otherwise; there is insufficient safety data. <li>Reasoning: Government/clinical summaries and reviews state limited evidence on safety of Boswellia in medicinal doses during lactation; absence of robust human data warrants caution. <li>Scientific_Study_Title: Boswellia: Usefulness and Safety (NCCIH summary) <li>Scientific_Study_Authors: National Center for Complementary and Integrative Health (NCCIH) <li>Scientific_Study_Link: https://www.nccih.nih.gov/health/boswellia <li>Scientific_Study_Excerpt: <p>The NCCIH summary indicates Boswellia is likely safe in amounts found in foods, and several clinical trials used oral extracts up to 1,000 mg daily without serious adverse events, but there is insufficient reliable information on its safety during pregnancy or breastfeeding. The agency recommends caution and consultation with healthcare providers before using Boswellia medicinally while pregnant or lactating because controlled safety data in these populations are limited or lacking.</p> </ul>